Re-Thinking Clinical Trials in Oncology
 Assessing the landscape of novel trial design for cancer therapies to improve data collection, enhance patient access, and drive clinical outcomes for breakthrough therapies

October 28, 2020 | Live Virtual Forum (EST)

Clinical Trials for cancer have evolved from being viewed as a last-ditch effort to the best chance of [a patient] getting cured. With the global pandemic bringing forth a relaxation in regulations from Agencies worldwide, the industry is currently asking itself what the future of oncology trial design and execution really looks like. How might new approaches in decentralized trials be done safely and effectively while also opening up the opportunity to tackle the traditional challenges associated with trial recruitment, engagement, diversity, and patient access? At the same time, there is a clinical rational for earlier phase trials in breakthrough therapies via IO, and novel approaches to trial design in the era of Precision Medicine and Biomarker Driven Therapies.

Join senior decision makers in clinical development to explore the benefits, opportunities and strategies to drive novel design approaches, evolve with the scientific landscape for cancer therapies, and accelerate breakthrough treatments to the patient.
    • What are the Lessons to be Learned from Ongoing Clinical Trials for Cancer Patients During the Global Pandemic?
    • Develop Regulator Strategies For Early Stages of Development to Understand What it Takes to Get New Products Approved
    • Understand how Under-representation of Minority Populations on Cancer Clinical Trials Impacts the Validity Of Trial Results and Can Exacerbate Health Disparities
    • Discuss How To Best Design Trials in The Age of Innovation
    • What is The Impact of “Big Data” and Data Analytics on Trial Design and Execution?

Featured Speakers

Event Sponsors

Create New Relationships that Deliver the Highest Value for your Current Networking Needs with:


LIVE event. No pre-recorded sessions


Social: Real-time Q&A between speakers and attendees during sessions, live polling, and direct messaging capability between attendees


Enhanced Networking: automated matchmaking suggestions based on your goals & interests. Use our virtual “meeting rooms” and set up 1:1 meetings.


Breakout networking rooms and room “hopping” capability

Brand Advisory Board

speaker name

Laurie Smaldone


NDA Group
speaker name

John Balchunus

Workforce Director

National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
speaker name

Vera Hoffman

CEO & Co Founder

Reveal Pharma
speaker name

John McShane

Managing Director

speaker name

Anton Xavier

Founder and CEO

K9 Biotech
speaker name

James Zanewicz

Chief Business Officer

Tulane University